Perrigo Company (PRGO) Reaches New Lifetime High Today

Editor's Note: Any reference to TheStreet Ratings and its underlying recommendation does not reflect the opinion of TheStreet, Inc. or any of its contributors including Jim Cramer or Stephanie Link.

Trade-Ideas LLC identified Perrigo Company ( PRGO) as a new lifetime high candidate. In addition to specific proprietary factors, Trade-Ideas identified Perrigo Company as such a stock due to the following factors:

  • PRGO has an average dollar-volume (as measured by average daily share volume multiplied by share price) of $222.0 million.
  • PRGO has traded 1.3 million shares today.
  • PRGO is trading at a new lifetime high.

EXCLUSIVE OFFER: Get the inside scoop on opportunities in PRGO with the Ticky from Trade-Ideas. See the FREE profile for PRGO NOW at Trade-Ideas

More details on PRGO:

Perrigo Company, through its subsidiaries, develops, manufactures, and distributes over-the-counter (OTC) and generic prescription (Rx) pharmaceuticals, nutritional products, and active pharmaceutical ingredients (API). The stock currently has a dividend yield of 0.2%. PRGO has a PE ratio of 30.6. Currently there are 11 analysts that rate Perrigo Company a buy, no analysts rate it a sell, and 4 rate it a hold.

The average volume for Perrigo Company has been 1.1 million shares per day over the past 30 days. Perrigo has a market cap of $13.7 billion and is part of the health care sector and drugs industry. The stock has a beta of 0.14 and a short float of 12.6% with 7.84 days to cover. Shares are up 39.7% year to date as of the close of trading on Thursday.

STOCKS TO BUY: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12-months. Learn more.

TheStreetRatings.com Analysis:

TheStreet Quant Ratings rates Perrigo Company as a buy. The company's strengths can be seen in multiple areas, such as its robust revenue growth, growth in earnings per share, good cash flow from operations, expanding profit margins and increase in stock price during the past year. Although no company is perfect, currently we do not see any significant weaknesses which are likely to detract from the generally positive outlook.

Highlights from the ratings report include:
  • The revenue growth came in higher than the industry average of 2.8%. Since the same quarter one year prior, revenues rose by 21.3%. This growth in revenue appears to have trickled down to the company's bottom line, improving the earnings per share.
  • PERRIGO CO has improved earnings per share by 5.3% in the most recent quarter compared to the same quarter a year ago. The company has demonstrated a pattern of positive earnings per share growth over the past two years. We feel that this trend should continue. During the past fiscal year, PERRIGO CO increased its bottom line by earning $4.67 versus $4.18 in the prior year. This year, the market expects an improvement in earnings ($6.58 versus $4.67).
  • Net operating cash flow has significantly increased by 120.04% to $98.70 million when compared to the same quarter last year. In addition, PERRIGO CO has also vastly surpassed the industry average cash flow growth rate of -44.16%.
  • 43.28% is the gross profit margin for PERRIGO CO which we consider to be strong. It has increased from the same quarter the previous year. Regardless of the strong results of the gross profit margin, the net profit margin of 11.93% trails the industry average.
  • The stock has risen over the past year as investors have generally rewarded the company for its earnings growth and other positive factors like the ones we have cited in this report. The stock's price rise over the last year has driven it to a level which is somewhat expensive compared to the rest of its industry. We feel, however, that other strengths this company displays justify these higher price levels.

STOCKS TO BUY: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12-months. Learn more.

null

More from Markets

Jim Cramer: Centene Is in All the Big Medicare Markets

Jim Cramer: Centene Is in All the Big Medicare Markets

Jim Cramer on the Markets: I Struggle With How Negative Things Are

Jim Cramer on the Markets: I Struggle With How Negative Things Are

Video: Jim Cramer on Tariff Worries, Oil, Alphabet and Centene

Video: Jim Cramer on Tariff Worries, Oil, Alphabet and Centene

Emerging Markets Get Pounded by Trade War Concerns

Emerging Markets Get Pounded by Trade War Concerns

Dow Tumbles, Stocks Slide on Renewed Trade War Concerns

Dow Tumbles, Stocks Slide on Renewed Trade War Concerns